The present invention relates to a pharmaceutical oral fixed dose combination comprisinga) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof,b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof,wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.
